AzTrials
AzTrials

Retinopathy of PrematurityNCT03154723

Effects of Early Vitamin A Supplementation on the Risk for Retinopathy of Prematurity in Extremely Preterm Infants

A study testing Vitamin A in people with Retinopathy of Prematurity, run by Huiqing Sun at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Retinopathy of prematurity (ROP) is a common retinal neovascular disorder and major cause of vision impairment or blindness, despite current treatment of late stage ROP. Because the visual disorders after treatment are often poor, preventive therapy for ROP is still lacking. Read more about this study

Who is it for?
Ages 1 hour to 45 weeksHealthy volunteers can take part
Conditions the study is for
Retinopathy of Prematurity
What is being tested?
Vitamin A
Could I receive a placebo?
No, everyone receives an active treatment
How many people
262 participants
Where
1 siteChina
Study dates
1 Aug 2015to 31 Dec 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 hour to 45 weeks
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • gestational age <28 weeks, <72 h of age, receiving mechanical ventilation, noninvasive respiratory support or supplemental oxygen (FiO2>0.21) at 24h of age.

Who cannot join

  • genetic metabolic diseases, congenital abnormalities, congenital nonbacterial infection with overt signs at birth, terminal illness as evidenced by PH<7.0 for >2h or persistent bradycardia (heart rate <100 bpm) associated with hypoxia for >2h, or grade III or IV intracranial hemorrhage before randomization were excluded

Trial locations and contacts

1 site in 1 country.

China1 site
  • Zhengzhou Children's Hospital

    Zhengzhou, Henan, 450018

Other trials in China

About this study

Retinopathy of prematurity (ROP) is a common retinal neovascular disorder and major cause of vision impairment or blindness, despite current treatment of late stage ROP. Because the visual disorders after treatment are often poor, preventive therapy for ROP is still lacking. Although ROP is a multifactorial disease, the altered regulation of vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF-1) have been implicated in the pathogenesis of ROP. Vitamin A is one of the most important micronutrients affecting the health of children. Supplementing newborn infants with vitamin A within the first 2 days of life reduced infant mortality by almost 25%, with the greatest benefit to those of low birth weight. Vitamin A has been used in this population prophylactically for chronic lung disease with the large doses and no reported significant adverse effect exists. It is suggested that vitamin A-retinoids and their active metabolite, retinoic acid (RA) have highly potent antiangiogenic activity by inhibiting VEGF expression. Vitamin A (retinol) is converted into retinoic acid in cells. However, the significance of Vitamin A administration has not been investigated to our knowledge in an experimental ROP infant. The aim of this study was to perform prospective, multicenter, randomized design to demonstrate the preventive effect of Vitamin A on ROP.

Read the detailed description

Retinopathy of prematurity (ROP) is a common retinal neovascular disorder and major cause of vision impairment or blindness, despite current treatment of late stage ROP. Because the visual disorders after treatment are often poor, preventive therapy for ROP is still lacking. Although ROP is a multifactorial disease, the altered regulation of vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF-1) have been implicated in the pathogenesis of ROP. The vascular endothelial growth factor (VEGF) is a hypoxia-inducible cytokine and a vascular endothelial cell mitogen. If VEGF is suppressed, normal vessel growth is inhibited, but if in excess, retinal neovascularization is precipitated. This indicates that VEGF is a critical factor in retinal neovascularization. Inhibition of VEGF at the neovascular phase might prevent destructive neovascularization. However, the choice of any intervention for the inhibition of VEGF should be taken into account very carefully, because VEGF also promotes normal physiological development of blood vessels in many tissues. In addition, this intervention can be applied to all preterm infants when potential side effects are almost minimal.

Vitamin A is one of the most important micronutrients affecting the health of children. Supplementing newborn infants with vitamin A within the first 2 days of life reduced infant mortality by almost 25%, with the greatest benefit to those of low birth weight. Vitamin A has been used in this population prophylactically for chronic lung disease with the large doses and no reported significant adverse effect exists. It is suggested that vitamin A-retinoids and their active metabolite, retinoic acid (RA) have highly potent antiangiogenic activity by inhibiting VEGF expression. Vitamin A (retinol) is converted into retinoic acid in cells. However, the significance of Vitamin A administration has not been investigated to our knowledge in an experimental ROP infant. The aim of this study was to demonstrate the preventive effect of Vitamin A on ROP.

Methods

This prospective, multicenter, randomized study was performed from August 2015 to March 2017 in neonatal intensive care units in China. This study was approved by the Life Science Ethics Committee of Zhengzhou University and the local research ethics committees at the participating centers. Written informed consent was obtained from both parents when an infant was admitted to the NICU.

Patient Population

Patients eligible for the study were extremely preterm infants admitted to the NICU with gestational age <28 weeks, <72 h of age, receiving mechanical ventilation, noninvasive respiratory support or supplemental oxygen (FiO2>0.21) at 24h of age. Infants with genetic metabolic diseases, congenital abnormalities, congenital nonbacterial infection with overt signs at birth, terminal illness as evidenced by PH<7.0 for >2h or persistent bradycardia (heart rate <100 bpm) associated with hypoxia for >2h, or grade III or IV intracranial hemorrhage before randomization were excluded, as were infants for whom parental consent could not be obtained.

Randomization

Subjects were assigned to the oral vitamin A group or the placebo group based on a computer-generated randomization plan. The allocation ratio was 1:1, using variable block sizes. Randomization to the oral vitamin A group or the placebo group was carried out by random number allocation sequence, upon securing the order of admission to the NICU, and within 30 min after written informed consent was obtained.

Vitamin A administration

Subjects will be given the daily dose 1500 IU/day in drop form added to their enteral feeds as soon as minimal feeding is introduced. All extremely preterm infants will be provided with basic administration of an intravenous multivitamin (1ml/kg/day, containing vitamin A 230 IU/kg/day) preparation whilst on parenteral nutrition until fully enterally fed.

Data Collection

All vital signs, including blood pressure, heart rate, oxygen saturation, ventilator settings, and arterial blood gases, were monitored both before and during mechanical ventilation. The primary outcomes were mortality and incidence of BPD, as determined by an oxygen reduction test at 36 weeks of postmenstrual age, and further graded by severity, using criteria adapted from the National Institute of Child Health and Human Development. Mild BPD was defined as the need for supplemental oxygen for <28 days. Moderate BPD was defined as the need for supplemental oxygen at postmenstrual age of 36 weeks without positive pressure support. Severe BPD was defined as the need for mechanical ventilation.

Secondary outcomes were days on mechanical ventilation, hospital stay, surfactant requirement, and the occurrence of retinopathy of prematurity stage 2 or higher, pulmonary hemorrhage, patent ductus arteriosus, necrotizing enterocolitis, or pneumothorax. Doctors were blind as to group allocation during the whole study.

Statistical Analyses

The minimum sample size of 127 in each group (total 254) was estimated based on an expected incidence of ROP (including mild, type 1 and type 2 ROP) in the control group of 62%, a 2-sided significance level of 0.05, and an 80% chance of detecting a relative 30% decrease infrequency. Analyses were performed according to the intention-to-treat principle, and all who could be evaluated were included.

All analyses were performed with statistics software (SPSS 17.0, SPSS Chicago, Illinois). Quantitative data are expressed as mean ± SD. Entry data and outcome differences were compared with the t test and Fisher exact test. Subgroup interaction analyses were performed on the basis of sex, birth weight, single or multiple births, antenatal steroid or postnatal surfactant treatment, and intubation time for mechanical ventilation. All subgroup statistical analyses were evaluated with the Breslow-Day test for interaction. The kappa test was used to examine whether the results were consistent between the 2 centers. The level of statistical significance was set at P <0 .05.

Being tested
Vitamin A
Medical subject headings
Retinopathy of Prematurity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Vitamin ADrug

    Also called Retinoic acid

    Vitamin A daily dose 1500IU/day will be added to infant's enteral feeds in drop form as soon as minimal feeding is introduced. The vitamin A supplementation was last for 28 days.

Study groups in NCT03154723
Study groupRoleWhat they receive
Vitamin A GroupExperimentalIn vitamin A group, The extremely preterm infants will be given the daily dose 1500 IU/day in drop form added to their enteral feeds as soon as minimal feeding is introduced.The duration of vitamin A supplementation was 28 days.
Receives: Drug: Vitamin A

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The rates of Retinopathy of Prematurity

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 May 2017
  2. Study start1 Aug 2015
  3. Primary completion31 Dec 2017
  4. Study completion31 Dec 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
262 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03154723
Sponsor's protocol ID
VitA-ROP
Status last verified
Aug 2018
First submitted
7 Apr 2017
Last updated
5 Sep 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Vitamin A in people with Retinopathy of Prematurity, run by Huiqing Sun at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The rates of Retinopathy of Prematurity (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in